• If you are wondering whether Corteva at around US$77 a share still offers value or is starting to look stretched, the next few sections will help you frame that question clearly.
• The stock has pulled back recently, with returns down 3.9% over the past week and down 7.7% over the past month, although it remains up 14.3% year to date and 9.8% over the past year.
• Recent headlines around Corteva have focused on its position within the wider materials sector and how investors are reassessing risk and reward for agricultural and chemical businesses. This helps explain some of the short term share price moves and provides important context as you assess whether the current price properly reflects the company’s long term prospects.
• Corteva currently scores 3 out of 6 on our valuation checks. Next comes a closer look at how different valuation approaches frame that score, followed by an even more practical way to think about value that is saved for the end of the article.

Approach 1: Corteva Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value.

For Corteva, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $2.0b. Analysts provide explicit free cash flow estimates up to 2029, with projected free cash flow of $2.9b in 2029. For the years out to 2035, Simply Wall St extends those analyst estimates to build a full 10 year cash flow path, then discounts each of those future cash flows back to today using its chosen rate.

Bringing those discounted cash flows together results in an estimated intrinsic value of about $107.71 per share. Against a current share price around $77, the model suggests Corteva trades at roughly a 28.1% discount to this DCF estimate, which indicates the stock appears undervalued on this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corteva is undervalued by 28.1%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Corteva Price vs Earnings

For profitable companies, the P/E ratio is a widely used yardstick because it links what you pay for the stock to the earnings the business is already generating. It helps you see how much the market is paying for each dollar of profit.

What counts as a “normal” P/E depends on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth or higher risk typically point to a lower multiple.

Corteva currently trades on a P/E of about 41.4x. That sits above the Chemicals industry average of about 27.8x and below the peer group average of roughly 54.3x. Simply Wall St’s Fair Ratio for Corteva is 25.5x. This is its proprietary view of what a reasonable P/E might be for this stock based on factors such as earnings growth, profit margins, industry, market cap and specific risks.

Because the Fair Ratio folds these company specific drivers into a single yardstick, it can be more informative than simply lining the stock up against peers or the broad industry.

Comparing Corteva’s current P/E of 41.4x with the Fair Ratio of 25.5x suggests the stock screens as overvalued on this measure.

Result: OVERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Corteva Narrative

Earlier there was mention of an even better way to understand valuation. Meet Narratives, a simple way for you to set out your story for Corteva by linking your assumptions for future revenue, earnings, margins and fair value to the company’s actual financial forecast. You can then compare that fair value with the current price on Simply Wall St’s Community page, where Narratives are updated automatically when new information such as earnings or news arrives. One investor might build a Corteva Narrative around the more optimistic analyst view with earnings of about US$2.7b and a higher fair value, while another might anchor on the more cautious US$2.1b earnings view and a lower fair value. You can see both side by side to decide which better matches your own expectations.

Do you think there's more to the story for Corteva? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.